Perrigo Makes Softgel Move As Mylan Continues Takeover Play
This article was originally published in The Tan Sheet
Executive Summary
Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.
You may also be interested in...
Mylan’s ‘Investor Logic’ For Acquisition Could Support Perrigo’s Rejection
Mylan targeted Perrigo as soon as it could, after acquiring Abbott Laboratories’ non-U.S. developed markets in June 2014, says CEO Heather Bresch. Her remarks at investor conference could lend support to Perrigo’s argument that Mylan’s offer does not acknowledge the value of its Omega Pharma acquisition.
Mylan’s ‘Investor Logic’ For Acquisition Could Support Perrigo’s Rejection
Mylan targeted Perrigo as soon as it could, after acquiring Abbott Laboratories’ non-U.S. developed markets in June 2014, says CEO Heather Bresch. Her remarks at investor conference could lend support to Perrigo’s argument that Mylan’s offer does not acknowledge the value of its Omega Pharma acquisition.
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba